Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China

What this Trial Is About

Researchers are conducting a large observational study focused on fibrotic Interstitial Lung Disease (f-ILD), including pneumoconiosis, to better understand the clinical characteristics linked to the development, progression, and outcomes of pulmonary fibrosis. The study aims to enroll at least 10,000 cases with continuous and regular follow-up to reveal important clinical phenotypes. It also seeks to evaluate different lung biopsy techniques and optimize histological diagnosis methods for f-ILD. This study plans to develop an artificial intelligence (AI) system for quantifying pulmonary fibrosis severity and create application software for clinical use. It will also explore and validate key molecular targets and biomarkers related to fibrosis formation. By integrating clinical features, imaging, pathology, and biomarkers, the study intends to build early recognition and progression models, intervention strategies, and guidelines applicable across the country. Participants will be followed for up to six years, during which researchers will assess outcomes such as clinical diagnostic protocols for lung tissue biopsy, prediction models, AI-based fibrosis severity evaluation using high-resolution CT scans, cohort development, and identification of important molecular targets through multi-omics analysis. The study involves regular data collection and follow-up visits to monitor disease progression and evaluate these outcomes.

Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China